Published in Medicine and Law Weekly, July 1st, 2005
The orphan drug status becomes effective when the European Commission has approved this recommendation. 1D09C3 is currently in a phase I clinical trial that is evaluating the antibody in patients with relapsed or refractory B-cell lymphomas, including Hodgkin and non-Hodgkin lymphomas, who have failed prior standard therapy.
1D09C3 is an anti-major histocompatibility complex (MHC)...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.